Sleuth Intelligence Community

Go deeper on Sleuth’s intelligence

Apply to join a small cohort of BD, strategy, and investment people in biopharma. You get the data behind each Intel Hub report, you can ask questions of the analysts who wrote it, and you can compare notes with peers.

Deep Dive

T-cell engagers intelligence report, Q3 2026

Autoimmune went from no deals before 2024 to the field’s busiest new lane.

Autoimmune programs

Program

Target

Lead indication

Highest stage

mosunetuzumab

CD20

SLE

Phase 2

Cizutamig

BCMA

Myasthenia gravis

Phase 1

CND261

CD20

Rheumatoid arthritis

Phase 1/2

Gamgertamig

BCMA

Autoimmune cytopenias

Phase 1/2

Ask the analysts who wrote it

Each new report gets its own thread in your cohort’s channel, where the analysts who built it answer questions. It’s the same team that builds the reports and delivers Sleuth’s Concierge projects.

How they built it

Ask what they counted, what they left out, and why a chart looks the way it does.

What they’d watch next

Each thread opens with the report’s predictions for the future, so you can debate the team and your peers.

What you’re working on

Tell them the question on your desk. It can shape what they analyze next.

ThreadT-cell engagers, Q3 2026

Sleuth analystAnalyst, Sleuth

T-cell engagers, Q3 2026 is up, with its workbook. Our call: autoimmune is the next test for T-cell engagers.

Open the data explorer

MemberBD, mid-size biotech

How many of the autoimmune deals since 2024 licensed a China-sourced asset?

Sleuth analystAnalyst, Sleuth

13 of the 16. The Deals sheet has a China-origin column, so you can filter to them.

A small cohort of people doing your job

Members join in small cohorts, so you know who you’re talking to. You’re placed with BD, strategy, and investment people working on questions like yours.

Small on purpose

Each cohort has its own private channel. Other cohorts can’t read it, and new members join the next cohort instead of crowding yours.

Operators and investors

People at biotechs and pharma companies, plus the investors, bankers, and consultants who work with them, from the US, Europe, and Asia.

News, deals, and meetups

Beyond each report’s thread, members share news and deals, and find each other at conferences.

Apply to join a cohort

Membership is free, and you don’t need a Sleuth account. We read every application and invite you to the cohort that fits.

Who it’s for

BD, corporate strategy, and competitive intelligence at biotech and pharma companies

Investors, bankers, and consultants who work on biopharma

How it works

1

Apply with your work email

2

Sleuth reviews your application

3

You’re invited to your cohort’s Slack channel, with the workbooks unlocked

Run an analysis like ours on your own question

Set up in Claude, ChatGPT, or Copilot